Search results
Wait—Why Am I Not Losing Weight on Ozempic?
Parade· 3 hours agoOzempic is technically for the management of type 2 diabetes. The most significant "side effect" of the diabetes drug, weight loss, has made it sought...
Obesity: Does eating chili peppers increase or decrease risk?
Medical News Today· 1 day agoChili peppers are often recognized for their slight fat-burning and metabolism-boosting properties....
Added health benefits of Wegovy, Zepbound could attract more men, doctors say
Reuters via AOL· 3 hours agoEvidence that weight-loss drugs like Novo Nordisk's Wegovy and Eli Lilly's Zepbound can cut heart...
Analyst Report: Novo Nordisk
Argus Research via Yahoo Finance· 2 hours agoNovo Nordisk is a pharmaceutical company based in Denmark. Its key divisions include Diabetes Care, Obesity Care, and Rare Diseases. Key products include ...
Abbott Snags U.S. Clearance To Enter The Obesity Arena, Rivaling Dexcom
Investor's Business Daily· 1 hour agoThough Stelo is designed for people with diabetes, the over-the-counter availability almost...
Obesity Drug Leader In Buy Zone After Huge Gains
Investor's Business Daily· 5 days agoThe stock is also a holding on IBD Leaderboard and ranks first in the ethical drugs industry group. Novo Nordisk makes products to treat and manage ...
'American Idol' alum Mandisa died from complications of class III obesity. Here's what that means.
Yahoo Life· 5 days agoHowever, an individual’s risk of developing cardiometabolic diseases like hypertension, stroke and ...
What's the Difference Between Ozempic and Metformin, and Which One Is Right for You?
Parade via Yahoo News· 4 days agoOzempic is a GLP-1 medication approved by the FDA for treating Type 2 diabetes. "It is a brand name...
GLP-1 Discontinuation Less Common With Endocrinologists
Medscape· 8 hours agoPatients taking glucagon-like peptide 1 (GLP-1) receptor agonists for obesity appear to be...
Biophytis Announces Filing of an IND Application with the US FDA for its Phase 2 Study in Obesity
Digital Journal· 6 hours agoFood and Drug Administration (FDA) regarding its phase 2 OBA clinical study in obesity with BIO101 (20-hydroxyecdysone). The OBA study will assess the efficacy and safety ...